Research advances in the mammalian target of rapamycin signaling pathway and its inhibitors in treatment of hepatocellular carcinoma
10.3760/cma.j.issn.1007-3418.2018.01.018
- VernacularTitle: 雷帕霉素靶蛋白信号通路及其抑制剂在肝细胞癌中的研究进展
- Author:
Suzhen LI
1
;
Feng XU
2
;
Changqing SUN
3
;
Ping XU
1
,
4
Author Information
1. Graduate School, Anhui Medical University, Hefei 230032, China
2. Beijing Institute of Radiation Medicine, State Key Laboratory of Proteomics, National Center for Protein Sciences Beijing, Beijing Proteome Research Center, National Engineering Research Center for Protein Drugs, Beijing 102206, China
3. Joint Center for Translational Medicine, Tianjin Baodi Hospital, Tianjin 301800, China
4. Beijing Institute of Radiation Medicine, State Key Laboratory of Proteomics, National Center for Protein Sciences Beijing, Beijing Proteome Research Center, National Engineering Research Center for Protein Drugs, Beijing 102206, China
- Publication Type:Review
- Keywords:
Carcinoma, hepatocellular;
mTOR;
mTOR signaling pathway;
mTOR inhibitors
- From:
Chinese Journal of Hepatology
2018;26(1):77-80
- CountryChina
- Language:Chinese
-
Abstract:
Mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase in the downstream of the phosphatidylinositol 3-kinases (PI3K) family. This kinase plays an important role in the development and progression of hepatocellular carcinoma (HCC). Preclinical data demonstrate that 40%-50% of HCC patients have dysregulated expression of the effectors of the mTOR signaling pathway, and the activation of the mTOR pathway is associated with poorly differentiated tumors, early tumor recurrence, and poor survival/prognosis. This article reviews the research advances in the potential role of the mTOR signaling pathway and its inhibitors in the treatment of HCC.
